ABT : Summary for Abbott Laboratories Common Stoc - Yahoo Finance

U.S. Markets close in 3 hrs 36 mins

Abbott Laboratories (ABT)


NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
40.39-0.37 (-0.90%)
As of 12:24PM EST. Market open.
People also watch
ABBVBMYLLYJNJMRK
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close40.76
Open40.64
Bid0.00 x
Ask0.00 x
Day's Range40.35 - 40.71
52 Week Range36.00 - 45.79
Volume3,058,511
Avg. Volume9,127,508
Market Cap69.52B
Beta1.49
PE Ratio (TTM)26.66
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.06 (2.59%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com13 minutes ago

    [$$] Abbott Set for 12% EPS Growth

    Abbott Laboratories (ABT: NYSE) By Wells Fargo Securities ($40.76, Jan. 18, 2017) Following the closing of the St. Jude Medical acquisition on Jan. 4, we have updated our Abbott Laboratories model and ...

  • ACCURATE Study Confirms Superiority Of Abbott Laboratories (ABT) Dorsal Root Ganglion (DRG) Stimulation
    Insider Monkeyyesterday

    ACCURATE Study Confirms Superiority Of Abbott Laboratories (ABT) Dorsal Root Ganglion (DRG) Stimulation

    Abbott Laboratories (NYSE:ABT)‘s dorsal root ganglion (DRG) stimulation therapy has advantages over traditional spinal cord stimulation (SCS) in the treatment of patients suffering from complex regional pain syndrome (CRPS). This is according to the latest data that was published in the January edition of Pain. The publication highlighted the real-world insight both in a short-term […]

  • PR Newswireyesterday

    Abbott Announces European Launch of the Proclaim™ DRG Neurostimulation System for the Management of Chronic Neuropathic Pain

    ABBOTT PARK, Ill., Jan. 18, 2017 /PRNewswire/ -- Abbott (ABT) today announced the European launch of the new Proclaim™ DRG Neurostimulation System, designed to deliver dorsal root ganglion (DRG) stimulation to patients suffering from chronic neuropathic pain. Through the Proclaim platform's Bluetooth® wireless technology and iOS™ software, the Proclaim DRG Neurostimulation System offers patients a more intuitive therapy experience, compared to current systems with traditional controllers that can be difficult to operate. This new system will improve the experience of how patients interact with their device, which may lead more patients to consider DRG stimulation for the treatment of chronic neuropathic pain.